Variables Involved in the Discordance between HbA1c and Fructosamine: The Glycation Gap Revisited

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Zafon, Carles ^a,b   Ciudin, Andreea ^a,b   Valladares, Silvia ^a   Mesa, Jordi ^a,b   Simó, Rafael ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN;

AGED; ARTICLE; CREATININE BLOOD LEVEL; ERYTHROCYTE MEMBRANE; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCATION GAP; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEMBRANE TRANSPORT; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROTEIN GLYCOSYLATION; REPRODUCIBILITY;

ANALYSIS OF VARIANCE; CREATININE; DIABETES MELLITUS, TYPE 2; FRUCTOSAMINE; GLYCOSYLATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; METFORMIN; SPAIN;

EID: 84878934138     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066696     Document Type: Article

References (35)

1. Hare MJL, Shaw JE, Zimmet PZ, (2012) Current controversies in the use of haemoglobin A1c. J Intern Med 271: 227-236.
2. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986.
3. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 352: 837-853.
4. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes (2009) Diabetes Care. 32: 1327-1334.
5. Leslie RDG, Cohen RM, (2009) Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol 3: 635-643.
6. Soranzo N, (2011) Genetic determinants of variability in glycated hemoglobin (HbA(1c)) in humans: review of recent progress and prospects for use in diabetes care. Curr Diab Rep 11: 562-569.
7. Cosson E, Chiheb S, Cussac-Pillegand C, Banu I, Hamo-Tchatchouang E, et al. (2012) Haemoglobin glycation may partly explain the discordance between HbA(1c) measurement and oral glucose tolerance test to diagnose dysglycaemia in overweight/obese subjects. Diabetes Metab (epub ahead of print).
8. Armbruster DA, (1987) Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 33: 2153-2163.
9. Smart LM, Howie AF, Young RJ, Walker SW, Clarke BF, et al. (1988) Comparison of fructosamine with glycosylated hemoglobin and plasma proteins as measures of glycemic control. Diabetes Care 11: 433-436.
10. Cockram CS, Pui PC, Keung CC, Moon YS, Swaminathan R, (1990) A comparison of fructosamine and glycosylated haemoglobin measurements at a diabetic clinic. Diabetes Res Clin Pract 9: 43-48.
11. Koskinen P, Erkkola R, Viikari J, Mattila K, Irjala K, (1992) Blood glycated haemoglobin, serum fructosamine, serum glycated albumin and serum glycated total protein as measures of glycaemia in diabetes mellitus. Scand J Clin Lab Invest 52: 863-869.
12. Narbonne H, Renacco E, Pradel V, Portugal H, Vialettes B, (2001) Can fructosamine be a surrogate for HbA(1c) in evaluating the achievement of therapeutic goals in diabetes? Diabetes Metab 27(5 Pt 1): 598-603.
13. Cohen RM, (2007) A1C: does one size fit all? Diabetes Care 30: 2756-2758.
14. Cohen RM, Holmes YR, Chenier TC, Joiner CH, (2003) Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 26: 163-167.
15. Nayak AU, Holland MR, Macdonald DR, Nevill A, Singh BM, (2011) Evidence for consistency of the glycation gap in diabetes. Diabetes Care 34: 1712-1716.
16. Rodríguez-Segade S, Rodríguez J, Cabezas-Agricola JM, Casanueva FF, Camiña F, (2011) Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A1c). Clin Chem 57: 264-271.
17. Rodríguez-Segade S, Rodríguez J, García Lopez JM, Casanueva FF, Camiña F, (2012) Estimation of the glycation gap in diabetic patients with stable glycemic control. Diabetes Care 35: 2447-2450.
18. Lachin JM, Genuth S, Nathan DM, Rutledge BN, (2007) The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes 56: 1913-1921.
19. Chalew SA, McCarter RJ, Thomas J, Thomson JL, Hempe JM, (2005) A comparison of the Glycosylation Gap and Hemoglobin Glycation Index in patients with diabetes. J Diabetes Complicat 19: 218-222.
20. Cohen RM, Snieder H, Lindsell CJ, Beyan H, Hawa MI, et al. (2006) Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care 29: 1739-1743.
21. Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, et al. (2008) Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes 57: 2445-2452.
22. Sharif A, Baboolal K, (2010) Diagnostic application of the A(1c) assay in renal disease. J Am Soc Nephrol 21: 383-385.
23. Bloomgarden ZT, (2009) A1C: recommendations, debates, and questions. Diabetes Care 32: e141-147.
24. Shima K, Chujo K, Yamada M, Komatsu M, Noma Y, et al. (2012) Lower value of glycated haemoglobin relative to glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis. Ann Clin Biochem 49(Pt 1): 68-74.
25. Brooks AP, Metcalfe J, Day JL, Edwards MS, (1980) Iron deficiency and glycosylated haemoglobin A. Lancet 2: 141.
26. Kim C, Bullard KM, Herman WH, Beckles GL, (2010) Association between iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 33: 780-785.
27. El-Agouza I, Abu Shahla A, Sirdah M, (2002) The effect of iron deficiency anaemia on the levels of haemoglobin subtypes: possible consequences for clinical diagnosis. Clin Lab Haematol 24: 285-289.
28. Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT, (2011) Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes 3: 67-73.
29. Bennett WL, Balfe LM, Faysal JM (2012) AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings. J Manag Care Pharm 18(1 Suppl A):1-22.
30. Selvin E, Bolen S, Yeh H-C, Wiley C, Wilson LM, et al. (2008) Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 168: 2070-2080.
31. Bailey CJ, (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22: 215-224.
32. Rapin JR, Lespinasse C, Yoa R, Wiernsperger N, (1991) Erythrocyte glucose consumption in insulin-dependent diabetes: effect of metformin in vitro. Diabete Metab 17(1 Pt 2): 164-167.
33. Yoa RG, Rapin JR, Wiernsperger NF, Martinand A, Belleville I, (1993) Demonstration of defective glucose uptake and storage in erythrocytes from non-insulin dependent diabetic patients and effects of metformin. Clin Exp Pharmacol Physiol 20: 563-567.
34. Rizkalla SW, Elgrably F, Tchobroutsky G, Slama G, (1986) Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects, in type 1 and type 2 diabetic patients. Diabete Metab 12: 219-224.
35. Santos RF, Nomizo R, Bopsco A, Wajchenberg BL, Reaven GM, et al. (1997) Effect of metformin on insulin-stimulated tyrosine kinase activity of erythrocytes from obese women with normal glucose tolerance. Diabetes Metab 23: 143-148.